Thursday, February 28, 2013

TGT Q4 Earnings



Target Corp. (TGT) announced earnings Wednesday and stated that its fiscal fourth-quarter sales rose 6.8% to $22.37 billion while credit-card revenue was up 1.8% to $356 million. Gross profit fell 2% to $961 million from $981 million the previous year. Per-share profit increased to $1.47 from $1.45 a year earlier after a 2.8% decrease in shares outstanding. Analysts, on average, expected earnings of $1.48 per share. Adjusted earnings per share, excluding items such as costs related to Canada, rose to $1.65 from $1.49 a year ago. Same-store sales were up 0.4% and missed analysts' average target of 0.8%.  
Full-year 2012 sales increased 5.1 percent to $72.0 billion from $68.5 billion in 2011 with credit card revenue decreasing 4.1% to about $1.4 billion. Gross profit for 2012 increased 2.4% when compared to 2011. Per-share profit increased to $4.52 from $4.28 in 2011, a 5.6% increase.
Full-year gross margin rate decreased to 29.7% in 2012, compared to the 30.1% rate in 2011. Fiscal fourth-quarter SG&A expenses increased 9.1% from the previous year and Cost of Sales increased 7.1%, both of which could explain why profits fell despite the increase in sales. Target had a more promotional holiday season than expected and was hurt by rising gas prices and a payroll tax increase.
Target has stated that it is going to have a transition year and plans to open 124 new stores in Canada, more openings than it has ever had in a single year. These Canada plans cut earnings by 48 cents per share in 2012 and should trim earnings by about 45 cents in 2013. Target expects sales to rise only about 2% this year.
CEO Gregg Steinhafel cited painfully slow growth in the US economy as to why Target’s growth declined. In first quarter 2013, TGT expects adjusted EPS anywhere between $1.10 and $1.20. Yearly, the company expects adjusted EPS of $4.85 to $5.05. Shares fell about 1% to $63.46 after shares dropped as low as 3.7% during yesterday’s session.
I am bullish on TGT going forward as the company continues to provide affordable products while economic growth remains slow. The aggressive expansion into Canada represents a key driver in the long-term growth of the company.

-JonMichael Shekian

Chicago Bridge & Iron Release 4Q2012 Earnings



     Chicago Bridge & Iron(Ticker: CBI) reported fourth quarter earnings on Wednesday, reporting Net Income of $89.6 million, $.91 a share. This was 27% increase over 4Q last year, when Net Income was $70.6 million, or $.70 a share. Revenue for the quarter was $1.5 billion with new awards of $2.9 billion. The revenue was a 22.2% increase over Q4 revenue last year, which was $1.26 billion. The EPS of $.91 a share beat the 13 analysts polled by Thomas Reuters by 9.6%, as their estimate was $.83 a share. The company announced a special dividend of $.05, representing a yield .36%, to be given on March 28, with an ex-dividend day of March 14.
     CEO Phillip Asherman said of the quarter, “I am extremely pleased that CB&I has delivered another year of strong new awards and outstanding performance, resulting in double-digit backlog growth and earnings per share exceeding the top end of our expectations for 2012.” The company is beginning to successfully integrate their purchase of The Shaw Group, which was initially seen as a negative by investor and lead to a 14 % decrease in the shares of the company. Since, the company is once again trading at 52 week highs, with investors realizing the synergies of the acquisition and the expansion of CBI’s product line. As of Thursday, CBI was trading at $55.04 a share, an increase of 3.77% a share on the earnings news.

MET Q4 Earnings


     MetLife (MET) released fourth quarter and full year earnings. During the 4thquarter MetLife reported net income of $96 million, or $0.09 per share over consensus. The increase in net income was fuelled by increases in Operating earnings which totaled $1.4 billion, or $1.25 per share which represents a 10% increase over fourth quarter earnings last year. The operating earnings beat consensus of 1.2 billion or ($1.17) per share.  Growth was driven by a 21% increase over earnings in the Americas and a 26% increase in their (EMEA) segments. In addition MetLife also suffered a 24% loss in earnings in Asia due to an annual review of actuarial assumptions.

     For the full year of 2012, MetLife reported earnings of $5.7 billion, or $5.28 per share, which represents a 22% increase over 2011. These earnings beat consensus of $5.5 billion in revenue or ($5.25) a share. The overall operating earnings for the Americas increased 21% to $1.3 billion driven by funding in Latin America. MetLife took a $70 million dollar hit in losses due to Super storm Sandy; this was above the company’s quarterly plan provision. To offset losses MetLife increased their premium and fee amounts which overall are up $9.9 billion or 18%. Due to the calm nature of the rest of the year MetLife was able to offset the losses and finished with a 5% increase in revenue for Americas.

     Although MetLife reported positively on both the quarter and the full year results, it still did not perform up to expectations. The stock dropped 2.5% following the earnings announcement however some of the drop was alleviated with news that MetLife is no longer a bank holding company. MetLife has been fighting for the past few years to drop its bank holding division and they were finally approved by the FDIC on Feb 14. MetLife sold off its main Bank’s depository business to General Electric Capital on January 11. The CEO of MetLife said they sold this segment so they could focus on insurance. The biggest weakness that MetLife currently faces is its large exposure to the weak European economy. Although many analysts are skeptical on the European market MetLife reported positively this past quarter and to offset some risk they are expanding into many different territories.

     By focusing on only insurance I believe there is a good opportunity for MetLife to focus on the segments it already owns and grow organically outward. MetLife is currently bidding on Citigroup’s United Kingdom Assurance division which would give them a dominate position in the United Kingdom insurance division. Although the results of the acquisition won’t come to light for a few more weeks, I believe this is a good indication that MetLife will be actively expanding. I believe because of this mix of expansion and organically growing its infrastructure we should expect a return on our investment in the near future.

-Logan Lyke

Wednesday, February 27, 2013

MET 4Q Earnings


            MetLife(MET) released fourth quarter and full year earnings. 
During the 4th quarter MetLife reported net income of $96 million, or $0.09 per share over consensus. The increase in net income was fuelled by increases in Operating earnings which totaled $1.4 billion, or $1.25 per share which represents a 10% increase over fourth quarter earnings last year. The operating earnings beat consensus of 1.2 billion or ($1.17) per share.  Growth was driven by a 21% increase over earnings in the Americas and a 26% increase in their (EMEA) segments. In addition MetLife also suffered a 24% loss in earnings in Asia due to an annual review of actuarial assumptions.
 
For the full year of 2012, MetLife reported earnings of $5.7 billion, or $5.28 per share, which represents a 22% increase over 2011. These earnings beat consensus of $5.5 billion in revenue or ($5.25) a share. The overall operating earnings for the Americas increased 21% to $1.3 billion driven by funding in Latin America. MetLife took a $70 million dollar hit in losses due to Super storm Sandy; this was above the company’s quarterly plan provision. To offset losses MetLife increased their premium and fee amounts which overall are up $9.9 billion or 18%. Due to the calm nature of the rest of the year MetLife was able to offset the losses and finished with a 5% increase in revenue for Americas.
            Although MetLife reported positively on both the quarter and the full year results, it still did not perform up to expectations. The stock dropped 2.5% following the earnings announcement however some of the drop was alleviated with news that MetLife is no longer a bank holding company. MetLife has been fighting for the past few years to drop its bank holding division and they were finally approved by the FDIC on Feb 14. MetLife sold off its main Bank’s depository business to General Electric Capital on January 11. The CEO of MetLife said they sold this segment so they could focus on insurance. The biggest weakness that MetLife currently faces is its large exposure to the weak European economy. Although many analysts are skeptical on the European market MetLife reported positively this past quarter and to offset some risk they are expanding into many different territories. 
            By focusing on only insurance I believe there is a good opportunity for MetLife to focus on the segments it already owns and grow organically outward. MetLife is currently bidding on Citigroup’s United Kingdom Assurance division which would give them a dominate position in the United Kingdom insurance division. Although the results of the acquisition won’t come to light for a few more weeks, I believe this is a good indication that MetLife will be actively expanding. I believe because of this mix of expansion and organically growing its infrastructure we should expect a return on our investment in the near future.

-Logan Lyke

Thursday, February 21, 2013

Actavis beat estimates; Future looks promising



Actavis (NYSE:ACT) posted Q4 earnings on Tuesday, February 19th 2012. Net revenues were $1.7B, with over $1.4B coming from Actavis Pharma, up from $1.5B and $1.2B, respectively, y/y. The inclusion of legacy Actavis was a large driver in creating this spread. Expenses were particularly high this quarter, with R&D growing 80% to $121.1M and SG&A growing 99% to $424.3M. Total operating expenses for Q4 grew 21.4% to $1.7B from $1.4B, driving margins down. Non-GAAP EPS was down 10.2% from $1.77 to $1.59; 4Q11 generated $0.64 in EPS from inclusion of LIPITOR, but dipped to $0.03 for 4Q12. Non-GAAP EPS beat Analyst estimates by $0.06.

Major pipeline drugs and marketed products have been added to the Actavis portfolio, primarily due to the acquisition of Uteron Pharma in January 2013, and the merger with Watson Pharmaceuticals in 2012. The Actavis pipeline is growing quick: “Our Actavis Pharma pipeline is among the strongest in the industry with over 185 Abbreviated New Drug Applications (ANDAs) on file with the US FDA, including 49 first-to-file opportunities, of which, 33 represent potential exclusive first-to-files.”

Going forward, there are many events that can either be a catalyst or a detriment to Actavis. Guidance projects net revenues to grow 37% to $8.1B. Non-GAAP EPS is expected to grow to $7.70 - $8.10, showing a potential upside between 28% - 35%. Many drugs are being pushed through the pipeline and we see them trying to break into new regions of the world. Analysts questioned when we could see their complex drugs get passed, and management stated they were unable to predict that because of the nature of the FDA process. Actavis is now trying to break into Australia, which they acknowledge would be tough because of top 5 competitors taking 97% market share. If they want to break in, they need a way to cut costs to effectively sell their products. Again, these events can either be a catalyst or a detriment, but for now we reaffirm our buy thesis.


Wednesday, February 20, 2013

Life Technologies dips 8%



Life Technologies dropped 8 percent yesterday to $58.83 on news that potential buyout offers have disappeared because of the recent run up in the firm's market value. On Jan 18, Life Technologies released a press announcement confirming that the bank has hired bankers to conduct a "strategical review" of the company, fueling speculation that private equity firms and larger life sciences companies are looking to buy out the firm. That speculation led to the company reaching a new high of just below $65 a share. Due to the recent gain in stock price however, Thermo Fisher Scientific Inc has reportedly withdrawn their offer to buyout the company at current price levels. A potential deal with Thermo Fisher Scientific would compliment both companies' current portfolio of life sciences tools, although it is rumored that Thermo Fisher doubts their offer will be accepted by the Life Technologies' board at current price levels.

In more positive news yesterday, Life Technologies also released details of an expansion of their Ion Torrent systems. They announced about a dozen new products that the company expects to continue the push to become the market leader in bench top genome sequencers, already controlling about 60% of the market. There has been great demand for the company's sequencers, driving revenue growth in the fourth quarter.

Overall, the news is underwhelming and its disappointing to see that buyout talks have reportedly stalled between Life Technologies and its potential suitors. At its current price targets, the life sciences company is trading above average in both earnings and EV/EBITDA relative to its peers. We will be waiting to see how the stock performs today to decide whether to exclude it from the portfolio and will update if any decisions are made.

Anadarko Guidance

Today Anadarko released details of its 2013 capital program and guidance. 2013 is expected to be one of the best years in company history. Capital Expenditures are estimated to be within the range of $7.2-$7.6 billion and will focus on projects that are estimated to generate return rates between 30 and 100 percent. Sales volume is expected to increase 5 percent, with high margin oil sales justifying most of the increase. The increase in oil sales will be primarly driven by increased activity in the Wattenberg and Eagleford horizontal programs. Furthermore, Anadarko remains focused on creating value by advancing high margin international oil and deep water development mega projects in Mozambique, Ghana, and Algeria, as well as continuing a very active exploration program.

Anadarko closed at $80.37, down 4.47 percent primarily due to worries concerning the possibility of Quantitative Easing ending prematurely. Equities within the energy space suffered the most losses because they are primarily driven by prospects of future economic growth. An end to QE in addition to a possibility of the debt crisis going unsolved has sent investors fleeing.

Despite today's bear run I do not believe QE will end anytime soon because the Fed has not come close to reaching its goal of 6.5 percent unemployment. I do not believe the Fed will end QE before budget cuts are negotiated on the contrary, a new QE program might be necessary to absorb the impact they will have on the U.S. economy.